MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Pacific Biosciences of California Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.63 -7.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.63

Max

1.6600000000000001

Pagrindiniai rodikliai

By Trading Economics

Pajamos

384M

-42M

Pardavimai

2.6M

40M

Pelno marža

-105.442

Darbuotojai

575

EBITDA

367M

-36M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+21.34% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

69M

487M

Ankstesnė atidarymo kaina

9.02

Ankstesnė uždarymo kaina

1.63

Naujienos nuotaikos

By Acuity

42%

58%

124 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Pacific Biosciences of California Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-17 18:13; UTC

Pagrindinės rinkos jėgos

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

2025-10-17 17:05; UTC

Pagrindinės rinkos jėgos

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

2025-10-18 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-18 07:00; UTC

Uždarbis

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

2025-10-17 23:25; UTC

Įsigijimai, susijungimai, perėmimai

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

2025-10-17 22:15; UTC

Rinkos pokalbiai

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

2025-10-17 21:15; UTC

Rinkos pokalbiai

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

2025-10-17 21:07; UTC

Rinkos pokalbiai

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

2025-10-17 21:07; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-17 20:34; UTC

Rinkos pokalbiai

Deere Is Reaching the End of Its Downcycle -- Market Talk

2025-10-17 20:27; UTC

Rinkos pokalbiai

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

2025-10-17 19:46; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025-10-17 19:45; UTC

Rinkos pokalbiai

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

2025-10-17 18:45; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

2025-10-17 17:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-17 17:51; UTC

Rinkos pokalbiai

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

2025-10-17 17:44; UTC

Rinkos pokalbiai

EQT Seen With Long-Term Growth Opportunities -- Market Talk

2025-10-17 17:35; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

2025-10-17 16:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-10-17 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-17 16:14; UTC

Rinkos pokalbiai

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

2025-10-17 16:04; UTC

Rinkos pokalbiai

Home Improvement Demand Is Starting to Pick Up -- Market Talk

2025-10-17 15:58; UTC

Rinkos pokalbiai

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

2025-10-17 15:56; UTC

Uždarbis

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

2025-10-17 15:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Pacific Biosciences of California Inc Prognozė

Kainos tikslas

By TipRanks

21.34% į viršų

12 mėnesių prognozė

Vidutinis 1.99 USD  21.34%

Aukščiausias 3 USD

Žemiausias 1.25 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pacific Biosciences of California Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

3

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.13 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

124 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat